Should Treatment Indications for Chronic Hepatitis B Be Expanded?

Background & AimAntiviral therapy has greatly improved the outcomes of patients with chronic hepatitis B virus (HBV) infection and active liver disease or advanced fibrosis/cirrhosis. However, current treatment does not eradicate HBV long-term is needed in most to maintain clinical benefit. Thus, professional society guidelines do recommend all infection. This review article will examine evidence for against expansion whom recommended based on guidelines.ResultsAvailable data support expanding immune tolerant grey zones who have active/advanced biopsy non-invasive tests those remain phase after age 40. Evidence supporting confirmed inactive carriers other lacking.ConclusionsHBV indications can be more liberal when new therapies that achieve HBsAg loss safely a high percentage finite course are available. Antiviral guidelines. Available lacking.